Search Results - "Battisti, NML"

Abstract P1-15-08: Pathologic complete response rates following neoadjuvant systemic therapy in 794 patients with early breast cancer: The Royal Marsden experience by Battisti, NML, True, V, Chaabouni, N, Chopra, N, Lee, K, Shepherd, S, Shapira-Rotenberg, T, Joshi, R, Mohammed, K, Allen, M, Ring, A

“…Background The presence and extent of residual invasive cancer after neoadjuvant treatment (NACT) is a strong prognostic factor for risk of recurrence,…”
Get full text

Geographical Variation in Underlying Social Deprivation, Cardiovascular and Other Comorbidities in Patients with Potentially Curable Cancers in England: Results from a National Registry Dataset Analysis by Waterhouse, J.V., Welch, C.A., Battisti, N.M.L., Sweeting, M.J., Paley, L., Lambert, P.C., Deanfield, J., de Belder, M., Peake, M.D., Adlam, D., Ring, A.

“…To describe the prevalence of cardiovascular disease (CVD), multiple comorbidities and social deprivation in patients with a potentially curable cancer in 20…”
Get full text

Abstract P6-18-23: Palbociclib and endocrine therapy in fourth line and beyond for hormone receptor-positive HER2-negative advanced breast cancer: The UK compassionate access program experience by Battisti, NML, Kingston, B, King, J, Denton, A, Waters, S, Sita-Lumsden, A, Rehman, F, Stavraka, C, Kristeleit, H, Sawyer, E, Houghton, D, Davidson, N, Howell, S, Choy, J, Harper, P, Roylance, R, Fharat, R, Mohammed, K, Ring, A, Johnston, S

“…Background Palbociclib is approved in 1st line for hormone receptor (HR)-positive HER2-negative advanced breast cancer (ABC). A Compassionate Access Program…”
Get full text